Abbott to Acquire Evalve

September 10, 2009—Abbott Vascular (Santa Clara, CA) announced a definitive agreement to acquire the outstanding equity of Evalve, Inc. (Menlo Park, CA). Evalve's minimally invasive, catheter-based MitraClip system is approved in Europe for nonsurgical mitral valve repair for patients with mitral regurgitation. The MitraClip system is an investigational device in the United States and is currently in clinical trials.

The transaction is expected to close in the fourth quarter of 2009, Abbott stated. Data from the EVEREST registries studying the MitraClip were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco. The presentations are summarized in the TCT Conference Coverage section of this issue of Cardiac Interventions Today (page 13).